10-Q · May 5, 2026
Spyre Therapeutics reported a significant increase in net loss to $69.0 million for Q1 2026, compared to a loss of $44.8 million in Q1 2025. Revenue was not generated during this quarter, as the company remains focused…
Earnings analysis · 10-Q
SYRE earnings analysis
Filed August 4, 2026 · Our reading of the company's report
The latest report
Spyre remains a pre-revenue clinical-stage biotechnology company, so revenue, margins and reported EPS are not disclosed in the provided filing text. Q2 net loss was $36.2 million, modestly better than $36.7 million a…
Read full summary
Spyre remains a pre-revenue clinical-stage biotechnology company, so revenue, margins and reported EPS are not disclosed in the provided filing text. Q2 net loss was $36.2 million, modestly better than $36.7 million a year earlier, but R&D rose 63% to $65.5 million as IBD and rheumatic-disease trials advanced. The investment case is supported by positive SPY001/SPY002 Phase 2 induction results and $1.1453 billion of liquidity, while elevated operating cash use of $127.2 million in the first half and clinical, manufacturing, and regulatory execution risks remain material.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Positive Phase 2 induction evidence
SPY001 and SPY002 met their SKYLINE Part A primary endpoints, with statistically significant RHI-score reductions of 9.2 points and 10.7 points, respectively. Clinical-remission rates were 40% for SPY001 and 33% for SPY002.
-
Quarterly loss stable despite R&D ramp
Quarterly net loss narrowed by $0.5 million year over year to $36.2 million, from $36.7 million, despite a $25.4 million, or 63%, increase in R&D spending to $65.5 million.
-
Liquidity substantially strengthened
The company ended June with $1.1453 billion in cash, cash equivalents and marketable securities after raising approximately $435.2 million of net proceeds in its April 2026 equity offering.
-
Multiple near-term clinical catalysts
SKYWAY enrollment is complete across all three sub-studies; rheumatoid arthritis topline data are expected in September 2026, while psoriatic arthritis and axial spondyloarthritis results are expected in the fourth quarter of 2026.
-
Investment concentrated in clinical pipeline
IBD external R&D expense increased $10.4 million, or 45%, to $33.6 million, and rheumatic-disease expense increased $7.6 million, or 243%, to $10.7 million, reflecting active pipeline advancement.
What to watch
-
High cash burn and eventual financing need
The company generated no product revenue and used $127.2 million in operating cash during the first six months of 2026, versus $87.6 million in the prior-year period; management says it will need additional capital in the future despite $1.1453 billion of current liquidity.
-
Clinical-development spending is accelerating
R&D expense increased 63% year over year to $65.5 million in Q2, including a 243% increase in rheumatic-disease external R&D expense to $10.7 million, increasing the operating-cost base ahead of pivotal-readout decisions.
-
China CMO and tariff-policy exposure
The filing expands emphasis on supply-chain and policy exposure: the company relies on foreign CMOs including China-based WuXi Biologics, while noting potential effects from the FY 2026 BIOSECURE Act and April 2026 U.S. tariffs on patented pharmaceutical products.
Management's outlook
No numeric financial guidance was provided. Management expects SPY003 SKYLINE Part A induction data in September 2026, SPY072 rheumatoid arthritis data in September 2026, and SPY072 psoriatic arthritis and axial spondyloarthritis data in the fourth quarter of 2026; SKYLINE Part B induction data are expected in 2027.
Earlier filings 4
10-K · February 19, 2026
Spyre is a clinical-stage, pre-revenue biotech advancing long‑acting antibodies for IBD and rheumatic diseases. The company reported encouraging Phase 1 PK and PD results (e.g., complete suppression of free TL1A through…
10-Q · November 4, 2025
Spyre remains a pre-revenue clinical-stage biotech but delivered a materially smaller GAAP loss in Q3 2025 driven by large other income; three‑month net loss narrowed to $(11,183) (from $(69,028) in Q3 2024) and basic…
10-Q · August 5, 2025
Spyre reported Q2 2025 results showing a modest sequential/year-over-year improvement in GAAP loss and EPS driven partly by a $10.0 million gain on sale of an IPR&D asset. The company remains pre-revenue, increased R&D…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.